STRATEGIC REPORT Financial review and principal risks The Group finished 2014 set to benefit from the actions and investments we have made Advanced Surgical Devices Advanced Wound Management Revenue split by franchise area % Revenue split by franchise area % OTHER ASD 4% ADVANCED WOUND BIOACTIVES 24% AET 16% KNEE 27% SPORTS MEDICINE 34% ORTHOPAEDIC RECONSTRUCTION $1,319m ADVANCED SPORTS MEDICINE 47% WOUND CARE $3,298m JOINT REPAIR 61% 18% ADVANCED WOUND DEVICES 15% HIP TRAUMA 20% EXTREMITIES 15% 1 1 Revenue by franchise area $m Revenue by franchise area $m 1% 2% 4% 8% 1% 10% -4% -9% 15% 2013 2014 2013 2014 2013 2014 2013 2014 2013 2014 2013 2014 2013 2014 2013 2014 2013 2014 ADVANCED ADVANCED ADVANCED HIPS KNEES TRAUMA & SPORTS MEDICINE AET OTHER ASD WOUND CARE WOUND DEVICES WOUND BIOACTIVES EXTREMITIES JOINT REPAIR ORTHOPAEDIC RECONSTRUCTION SPORTS MEDICINE 1 T he underlying percentage increases decreases are after adjusting for the effect of currency translation and the inclusion of the comparative impact of acquisitions and execution of disposals.
2 Explanation of these non-GAAP financial measures are provided on pages 176 to 179.
34 Smith & Nephew Annual report 2014 653 654 865 873 486 506 496 576 441 542 74 147 843 805 213 192 280 322 STRATEGIC REPORT CORPORATE GOVERNANCE FINANCIAL STATEMENTS AND OTHER INFORMATION Revenue by market The underlying increase in each divisions revenues, by market, reconciles to reported growth, the most directly comparable financial measure calculated in accordance with IFRS, as follows: Constant Reported currency Acquisition Underlying growth in exchange Disposal growth in 2014 2013 revenue effect effect revenue $ million $ million % % % % Advanced Surgical Devices US 1,558 1,391 12 10 2 Other Established Markets 1,229 1,204 2 2 4 Established Markets 2,787 2,595 7 1 7 1 Emerging & International Markets 511 420 22 3 8 17 Advanced Surgical Devices 3,298 3,015 9 1 7 3 Advanced Wound Management US 454 471 4 4 Other Established Markets 699 722 3 1 2 Established Markets 1,153 1,193 3 3 Emerging & International Markets 166 143 16 3 5 14 Advanced Wound Management 1,319 1,336 1 1 1 1 1% unfavourable foreign currency translation.
Sales in our VERILAST Advanced Surgical Devices Hip and direct anterior approach portfolio contributed to the increase.
Trauma & Extremities revenue increased by $20 million from Revenue $486 million in 2013 to $506 million in 2014 4% on a reported basis, ASD revenue increased by $283 million 9% on a reported basis representing underlying revenue growth of 4% after adjusting for from $3,015 million in 2013 to $3,298 million in 2014.
The underlying a 1% impact from the acquisition of a Brazilian distributor and 1% of increase of 3% is after adjusting for a 7% impact from the acquisition unfavourable foreign currency translation.
of ArthroCare Corp in May 2014 and a 1%unfavourable foreign Sports Medicine Joint Repair revenue increased by $80 million from currency translation.
$496 million in 2013 to $576 million in 2014 16% on reported basis, In the US, revenue increased by $167 million to $1,558 million in 2014 representing underlying revenue growth of 8% after adjusting for from $1,391 million in 2013 12% on a reported basis.
The underlying a 8% impact from the acquisition of ArthroCare Corp, 1% from the increase of 2% is after adjusting 10% for the impact of the ArthroCare acquisition of a Brazilian distributor and 1% of unfavourable foreign Corp acquisition in May 2014.
In Other Established Markets, currency translation.
revenue was $1,229 million in 2014, an increase of $25 million from Global revenue from Arthroscopic Enabling technologies increased $1,204 million in 2013 2% on a reported basis.
The underlying by $101 million from $441 million in 2013 to $542 million in 2014 23% increase was flat after adjusting for 2% from favourable foreign on a reported basis.
This increase represents an underlying revenue currency translation and the impact of 4% from acquisitions.
Our increase of 1% after adjusting for the 22% impact from the acquisition Emerging & International Markets revenue increased by $91 million of ArthroCare Corp, 1% from the acquisition of a Brazilian distributor to $511 million in 2014 from $420 million in 2013 22% increase on a and 1% of unfavourable foreign currency translation.
The underlying increase was 17% after adjusting for 3% for unfavourable foreign currency translation and the impact of 8% The revenue in the Other ASD including Gynaecology and ENT from acquisitions.
franchise increased by $73 million from $74 million in 2013 to $147 million in 2014 following the acquisition of ArthroCare Corp in In the global Knee Implant franchise, revenue increased by $8 million 2014.
Excluding the impact of this acquisition, underlying revenue in from $865 million in 2013 to $873 million in 2014 1% on a reported the Other ASD franchise, which includes gynaecology, grew by 10%.
basis, representing a 2% underlying revenue increase after 1% of unfavourable currency translation.
Growth has been impacted by exposure to a weakening European market with conditions continuing to deteriorate in Germany, our largest European market, and our position in the product life cycle versus our peers.
Growth improved driven by sales of the JOURNEY II BCS Knee System.
Global revenue from the Hip Implant franchise increased by$1 million from $653 million in 2013 to $654 million in 2014 flat on a reported basis, which represented an underlying revenue increase of 1% after Smith & Nephew Annual report 2014 35 STRATEGIC REPORT Financial review and principal risks continued Trading and operating profit Trading and operating profit Operating profit, the most directly comparable financial measure under Operating profit, the most directly comparable financial measure under IFRS, reconciles to trading profit as follows: IFRS, reconciles to trading profit as follows: 2014 2013 2014 2013 $ million $ million $ million $ million Operating profit 626 620 Operating profit 123 190 Acquisition-related costs 107 7 Acquisition-related costs 11 24 Restructuring and rationalisation costs 33 44 Restructuring and rationalisation costs 28 14 Amortisation of acquisition intangibles Amortisation of acquisition intangibles andimpairments 78 41 andimpairments 51 47 Legal and other 34 Legal and other 32 Trading profit 810 712 Trading profit 245 275 Trading profit margin increased from 23.6% to 24.6%.
Trading profit Trading profit margin decreased from 20.6% to 18.6%.
Trading profit increased by $98 million to $810 million from $712 million in 2013.
This decreased by $30 million to $245 million from $275 million in 2013. increase reflects the benefits from our structural efficiency programme.
The decrease in the year is primarily attributable to the RENASYS hold.
Operating profit increased by $6 million from $620 million in 2013 to Operating profit decreased by $67 million from $190 million in 2013 $626 million in 2014.
This comprises the increase in trading profit of to$123 million in 2014.
This comprises of the decrease in trading $98 million discussed above offset by increases in acquisition-related profit of $30 million discussed above, costs relating to the hold on costs of $100 million and amortisation of acquisition intangibles of RENASYS and cessation of the HP802 trials amounting $52 million, $37 million and partially offset by a decrease in restructuring and offset by a decrease in acquisition-related costs of $13 million, due rationalisation costs of $11 million and credit relating to the US pension to the integration of the Healthpoint acquisition which completed settlement and closure.
in December 2012, an increase in restructuring and rationalisation costs of $14 million and an increase of$4 million in amortisation of acquisition intangibles.
Advanced Wound Management Revenue Principal risks and risk management AWM revenue decreased by $17 million -1% on a reported basis, from As an integral part of planning and review Group, businessarea and $1,336 million in 2013 to $1,319 million in 2014.
The underlying decrease functional management seek to identify thesignificant risks involved of 1% is after adjusting for an increase of 1% for acquisitions completed in the business, and to review the risk management action plans for in the year and a 1% unfavourable foreign currency translation.
The Group Risk Committee, which is comprised of the Chief Executive Officer and senior executives, meets twice a year to In the US, revenue decreased by $17 million to $454 million in 2014 review the risks identified bythe businesses and corporate functions from $471 million in 2013 -4% on a reported basis.
The underlying and any risk management actions being taken.
As appropriate, the decrease was also 4%.
In Other Established Markets, revenue was Risk Committee may re-categorise risks or require further information $699 million in 2014, a decrease of $23 million from $722 million in on the risk management action plans.
The Risk Committee reports to 2013 -3% on a reported basis.
The underlying revenue decrease the Board on an annual basis detailing all principal risks.
In addition, was 2% with 1%of unfavourable foreign currency translation.
Our the Board considers risk as part of the development of strategy.
Internal Emerging & International Markets revenue increased by $23 million in audit reviews and the Audit Committee reports onthe effectiveness of 2014 16%on a reported basis.
The underlying increase was 14%after the operation of the risk management process.
adjusting 2% for unfavourable foreign currency translation.
There are known and unknown risks and uncertainties relating to Advanced Wound Care revenue decreased by $38 million -5% on Smith & Nephews business.
The following pages provide an overview areported basis to $805 million in 2014 from $849 million in 2013. of what the Board considers the most significant risks that could cause The underlying decline of 4% is after adjusting for foreign currency the Groups business, financial position and results of operations to translation.
Conditions across many European markets remain differ materially and adversely from expected and historical levels, and challenging but the introduction of the ALLEVYN Life range continues how these risks relate to the Groups strategic priorities.
Additional to make good progress across Europe following product introductions detail is set forth under Risk Factors in the Group information section and investment in marketing.
In addition, other factors not listed here that Smith & Advance Wound Devices revenue decreased from $213 million in2013 Nephew cannot presently identify or does not believe to be equally to $192 million in 2014, a reported decrease of $21 million and 10%.
significant, could also materially adversely affect Smith & Nephews The underlying decrease of 9% is after adjusting for unfavourable business, financial position or results of operations.
This decline was due to the hold of RENASYS in the US due to regulatory issues and competitive pressures in traditional canister-based NPWT in Europe.
Advanced Wound Bioactives revenue increase to $322 million in 2014 from $280 million in 2013 15% reported growth.
The underlying increase was also 15%.
36 Smith & Nephew Annual report 2014 STRATEGIC REPORT CORPORATE GOVERNANCE FINANCIAL STATEMENTS AND OTHER INFORMATION Group Risk Management Process Board oversight Business and Group Risk Corporate Function Group Risk Register Committee Risk Registers Process frequency: twice yearly Risk Champions arrange business Group Risk Committee considers Contains risks considered significantat function reviews and submit updated Risk submissions and decides which risks Group level Register & Mitigation Plans to Chief go into group-level risks Assigns responsibility for eachriskand Compliance and Risk Officer CCRO CCRO updates Group Risk Register mitigation plan toseniorexecutives Registers contain pertinent risks foreach and prepares reports for the Audit unit with mitigation plan Committee and the Board ofDirectors Product Portfolio Development The medical devices industry has a rapid rate of new product introduction.
The Group must be adept at monitoring the landscape for technological advances, have an efficient and valuable product development pipeline and secure protection for its intellectual property.
The Group may also seek to acquire businesses as part our business strategy to augment the product portfolio or business scale in a certain geography.
Specific risks we face Risk management actions Possible impacts Competitors may introduce a disruptive Processes focused on identifying new Loss of market share, profit technology, or obtain patents or other products and potential disruptive technologies and long-term growth intellectual property rights, that affect the internal and external Groups competitive position Improved productivity, prioritisation and Link to Strategic Priority Claims by third parties regarding infringement allocation of R&D funds of their intellectual property rights Innovate for value Increasing R&D investment to enhance clinical Lack of innovation due to low R&D investment, capability and invest in biomaterials Established Markets R&D skills gap or poor product development Strengthen intellectual property rights and execution for Established and Emerging & monitor and defend against infringement Emerging & International International markets Global strategic marketing programmes Markets Failure to receive regulatory approval to Support an Emerging & International Market successfully commercialise a pipeline product product portfolio Supplement organic growth through acquisitions Acquisitions and Business Development The Group may seek to acquire businesses or products as part of our strategy to augment the product portfolio or generate business scale in certain geographies.
These acquisitions must deliver the expected returns and not create significant liability exposures or the Group may not meet its financial targets.
Specific risks we may face Risk management actions Possible impacts Ineffective acquisition due diligence Strong resources and processes to ensure Loss of market share, profit rigorous review and integration of acquisitions and long-term growth Inflated forecasts or projections may cause or product related investments over-valuation of transaction Link to Strategic Priority Mergers & Acquisitions Council consisting of Lack of timely adoption of Group standards senior executives that reviews acquisitions and policies and financial controls during integration Emerging & International business development transactions could create additional liabilities Markets Board of Directors review of all significant Acquisitions in emerging markets may identify transactions practices that must be ceased to meet Group Supplement organic growth standards Detailed compliance due diligence and through acquisitions integration reporting processes Established Markets Robust Internal Audit and Group Finance Controls Post acquisition review programme Smith & Nephew Annual report 2014 37 STRATEGIC REPORT Financial review and principal risks continued Government Action, Pricing and Reimbursement Pressure In most markets throughout the world, expenditure on medical devices is controlled to a large extent by governments, many of which are facing increasingly intense budgetary constraints.
The Group is therefore largely dependent on governments providing increased funds commensurate with the increased demand arising from demographic trends.
Reimbursement rates may be set in response to perceived economic value of the devices, based on clinical and other data relating to cost, patient outcomes and comparative effectiveness.
Political upheaval in the countries where the Group operates or surrounding regions could adversely affect Group operations or turnover.
Group operations are affected by transactional exchange rate movements.
The Groups manufacturing cost base is situated in the US, UK, Costa Rica, China and Switzerland and finished products are exported worldwide.
Specific risks we face Risk management actions Possible impacts Reduced reimbursement levels and increasing Develop innovative economic product and Loss of revenue, profit and pricing pressures service solutions for both Established and cash flows Emerging & International markets Syncera Reduced demand for elective surgery Incorporate health economic component into Lack of compelling health economics design and development of new products data to support reimbursement requests Link to Strategic Priority Enhanced expertise supporting reimbursement Government policies favouring lower priced and strategy and guidance locally sourced products Simplify and improve Optimise cost to serve to protect margins and Political upheavals prevent selling of products, our operating model liberate funds for investment receiving remittances of profit from a member of the Group or future investments in that country Streamline Cost of Goods Sold, Stock Keeping Established Markets Units and inventory management The Group is exposed to fluctuations in exchange rates.
If the manufacturing country currencies The Group transacts forward foreign currency Emerging & International strengthen against the selling currencies, the commitments when firm purchase orders are Markets trading margin may be affected placed to reduce exposure to currency fluctuations Economic downturn impacts demand and collections Business Operations and Business Continuity Unexpected events could disrupt the business by affecting either a key facility or system or a large number of employees.
The business is also reliant on certain key suppliers of raw materials, components, finished products and packaging materials.
The Group manages a large product portfolio and a large product inventory.
Sales and operation planning and supply chain management must ensure the products needed are available at the right place and time.
In a fast changing, complex, global business, high performing talent in key positions is a business critical requirement.
Specific risks we face Risk management actions Possible impacts Catastrophe could render one of the Groups Crisis response business continuity plans at Loss of revenue, profit and production facilities out of action major facilities and for key products and key cash flows suppliers A significant event could impact key leadership or a large number of employees Audit programme for critical suppliers and second sources or increased inventories for Issues with a single source supplier of a key critical components Link to Strategic Priority component and failure to secure critical supply Enhanced travel security and protection A severe IT fault or cyber crime could disable Simplify and improve programme critical systems and cause loss of sensitive data our operating model IT disaster and data recovery plans in place Over-production of product inventory and to support overall business continuity plans instrument sets may occur due to inadequate Established Markets portfolio planning Mobile device and cyber security protection plan Poor retention of high performing and Improved sales and operations processes and Emerging & International high potential staff could jeopardise inventory management with dedicated teams Markets achieving objectives and key performance indicators Robust talent systems and processes with focus on identifying key roles and successors 38 Smith & Nephew Annual report 2014 STRATEGIC REPORT CORPORATE GOVERNANCE FINANCIAL STATEMENTS AND OTHER INFORMATION Product Safety, Regulation, and Litigation National regulatory authorities enforce a complex series of laws and regulations that govern the design, development, approval, manufacture, labelling, marketing and sale of healthcare products.
They also review data supporting the safety and efficacy of such products and may also inspect for compliance with appropriate standards, including those relating to Quality Management Systems QMS or Good Manufacturing Practice GMP regulations.
Design or manufacturing defects in products could result in product recalls and liability claims and impact revenues, profits and reputation.
Specific risks we face Risk management actions Possible impacts Defective products supplied to Smith & Nephew Global QARA organisation to create a single Loss of revenue, profit and or failure in design or manufacturing process Quality Management System reduction in share price New technology, product or processes changed Standardised Group quality management and Negative impact on brand by Smith & Nephew or supplier result in product practice reputation deficiencies Monitoring and auditing programmes to assure Failure to implement programmes and supporting compliance resources to ensure product quality and Group-wide product complaint and registration regulatory compliance Link to Strategic Priority systems Failure to manage, process and analyse customer Group-wide practices to drive design, and Simplify and improve complaints and adverse event data production line performance and dependability our operating model Design for manufacture in product development Post launch review of product safety and Established Markets complaint data Emerging & International Markets Compliance with Laws and Ethical Behaviour Business practices in the healthcare industry are subject to increasing scrutiny by government authorities.
The trend in many countries is towards increased enforcement activity for bribery and corruption.
The Group is also subject to increased scrutiny under US healthcare laws e. g. False Claims Act and in the EU for data protection.
Acquisitions and expansion into emerging markets may require additional compliance controls.
Specific risks we face Risk management actions Possible impacts Violation of anti-corruption, healthcare, or Strong Board and Executive oversight bodies Loss of profit and reduction data privacy laws could result in fines, loss of supported by a global Office of Ethics & Compliance in share price reimbursement and harm reputation Code of Conduct Global Policies and Procedures Negative impact on brand Cultures in certain geographies and in acquired GPPs providing guidelines for ethical behaviour reputation businesses may not fully support the Group and controls for significant compliance risks value to Earn Trust Training and e-resources to guide employees Rapid growth in Emerging & International Markets and third parties with ethical and compliance with increasing numbers of distributors responsibilities Link to Strategic Priority Third parties retained by the Group may be Monitoring and auditing programmes to verify Simplify and improve involved in improper activities which result in implementation our operating model penalties or loss of reputation.
Minimum acceptable financial procedures Failure to conduct adequate due diligence or adopted by all businesses wholly owned by Emerging & International to integrate appropriate internal controls into the Group Markets acquired businesses could result in fines and Independent reporting channels for employees impact return on investment and third parties to report concerns with Established Markets confidentiality Robust investigation procedures to ensure adequate reviews and documentation with significant issues escalated to and monitored by legal and compliance heads Controls for significant interactions with Health Care Professionals and Government Officials Higher risk third parties including distributors and agents subject to screening, compliance requirements, training and oversight processes Due diligence reviews and integration plans and reporting for acquisitions Risk assessments to determine resources and controls for higher risk markets Smith & Nephew Annual report 2014 39
